Pelthos Therapeutics Appoints New CFO John M. Gay
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Should l Buy PTHS?
Source: Newsfilter
- Executive Change: Pelthos Therapeutics has appointed John M. Gay as Chief Financial Officer effective April 10, 2026, succeeding Francis Knuettel II, who held the position since July 2025, indicating a strategic leadership transition during the company's growth phase.
- Financial Expertise: John M. Gay has served as Senior Vice President of Finance & Accounting at Pelthos for a year and brings over 25 years of public company finance and accounting experience, having held CFO roles at several publicly traded companies, showcasing Pelthos' confidence in his financial management capabilities.
- Strategic Implications: CEO Scott Plesha highlighted Gay's key role in establishing and launching Pelthos, indicating that the company is preparing for future commercial growth and market expansion, thereby strengthening its position in the biopharmaceutical industry.
- Acknowledgment of Predecessor: The company expressed gratitude for the contributions of former CFO Francis Knuettel II, particularly during the merger with Channel Therapeutics and two significant capital raises, reflecting Pelthos' emphasis on team stability and experience transfer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PTHS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PTHS
Wall Street analysts forecast PTHS stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.580
Low
50.00
Averages
60.40
High
75.00
Current: 22.580
Low
50.00
Averages
60.40
High
75.00
About PTHS
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pelthos Therapeutics Appoints New CFO
- New CFO Appointment: Pelthos Therapeutics announced the appointment of John M. Gay as CFO, effective April 10, 2026, succeeding Francis Knuettel II, marking a significant change in the company's financial leadership.
- Extensive Financial Experience: Gay brings over 25 years of public company finance and accounting experience, having served as the company's SVP of Finance & Accounting since 2025, demonstrating his strong background and leadership in finance.
- Previous Roles Overview: Prior to joining Pelthos, Gay served as CFO of LNHC and held senior positions at Furiex Pharmaceuticals, further enhancing his expertise in the biopharmaceutical sector.
- Future Growth Outlook: Pelthos Therapeutics is actively driving continued momentum for ZELSUVMI and plans to expand product launches through 2027, reflecting the company's confidence in future market opportunities.
See More
Pelthos Therapeutics Appoints New CFO John M. Gay
- Executive Change: Pelthos Therapeutics has appointed John M. Gay as Chief Financial Officer effective April 10, 2026, succeeding Francis Knuettel II, who held the position since July 2025, indicating a strategic leadership transition during the company's growth phase.
- Financial Expertise: John M. Gay has served as Senior Vice President of Finance & Accounting at Pelthos for a year and brings over 25 years of public company finance and accounting experience, having held CFO roles at several publicly traded companies, showcasing Pelthos' confidence in his financial management capabilities.
- Strategic Implications: CEO Scott Plesha highlighted Gay's key role in establishing and launching Pelthos, indicating that the company is preparing for future commercial growth and market expansion, thereby strengthening its position in the biopharmaceutical industry.
- Acknowledgment of Predecessor: The company expressed gratitude for the contributions of former CFO Francis Knuettel II, particularly during the merger with Channel Therapeutics and two significant capital raises, reflecting Pelthos' emphasis on team stability and experience transfer.
See More
Pelthos Appoints New Chief Financial Officer
- Executive Transition: Pelthos Therapeutics has appointed John M. Gay as Chief Financial Officer effective April 10, 2026, succeeding Francis Knuettel II, who held the position since July 2025, indicating ongoing leadership optimization to support future growth.
- Financial Leadership Experience: John M. Gay has served as Senior Vice President of Finance & Accounting at Pelthos for a year and brings over 25 years of public company finance and accounting experience, enhancing the company's financial management expertise.
- Commitment to Business Growth: CEO Scott Plesha noted that Gay played a key role in establishing and launching Pelthos, and his appointment as CFO aims to continue driving the company's commercial momentum, reflecting confidence in future development.
- Capital Raising Context: During Knuettel's tenure, Pelthos successfully completed two significant capital raises, and Gay's appointment is viewed as a strategic continuation of the company's integration and capital operations post-merger, aimed at further solidifying its market position.
See More
Pelthos Initiates Clinical Trial for CT2000 Eye Pain Treatment
- Clinical Trial Launch: Pelthos Therapeutics announced the initiation of a Phase 1b/2a clinical trial for CT2000 in Australia, with the first patient successfully dosed, marking a significant advancement in the company's eye pain treatment pipeline.
- Drug Potential Assessment: CT2000, a NaV1.7 inhibitor, aims to treat acute and chronic ocular pain associated with dry eye disease, with animal study results suggesting broad applications in various pain indications, potentially offering new therapeutic options for patients.
- Market Outlook: The global chronic ocular pain market is projected to reach $5.3 billion by 2032, positioning Pelthos' CT2000 to capture a significant share of this rapidly growing market and address unmet patient needs.
- Innovative Trial Design: The clinical trial features an adaptive design with a maximum tolerated dose study over 28 days, with results expected by the end of 2026, where successful clinical data could lay the groundwork for future commercialization efforts.
See More
Pelthos Therapeutics Reports Strong Q4 2025 Earnings Growth
- Significant Revenue Growth: Pelthos Therapeutics reported a net product revenue increase from $7.1 million in Q3 2025 to $9.1 million in Q4 2025, marking a 28% growth that indicates strong market demand for ZELSUVMI and improved overall financial performance.
- Surge in Prescriptions: ZELSUVMI prescriptions surged by 129% from Q3, reaching 6,232 units, reflecting not only the product's growing acceptance in the market but also the company's successful shift towards direct patient dispensing, which is expected to further drive revenue growth.
- Product Portfolio Expansion: The acquisition of FDA-approved products Xepi and Xeglyze, set to launch in 2027, enhances Pelthos's product line, strengthens market competitiveness, and provides new revenue growth avenues for the future.
- Improved Financial Position: As of December 31, 2025, Pelthos's cash balance rose to $18 million from $14.2 million in Q3, demonstrating effective cost control and operational optimization, thereby laying a solid foundation for future business expansion.
See More
Pelthos Therapeutics Reports Q4 Losses Despite Revenue Beat
- Disappointing Earnings: Pelthos Therapeutics reported a Q4 GAAP EPS of -$6.87, missing expectations by $3.84, indicating significant challenges in profitability that could undermine investor confidence.
- Slight Revenue Growth: Despite the EPS miss, Pelthos achieved revenue of $9.39M, beating market expectations by $0.3M, suggesting that the company still has some growth potential in sales, which may support future business development.
- Financing Initiative: Pelthos Therapeutics announced a $50 million senior secured loan facility, which will provide necessary liquidity to help stabilize its operations and R&D efforts, despite its current financial challenges.
- Market Reaction Analysis: Following the earnings report, market reactions to Pelthos may be influenced by its profitability and financing plans, prompting investors to closely monitor future strategic adjustments and market performance.
See More
Pelthos Therapeutics Appoints New CFO
- New CFO Appointment: Pelthos Therapeutics announced the appointment of John M. Gay as CFO, effective April 10, 2026, succeeding Francis Knuettel II, marking a significant change in the company's financial leadership.
- Extensive Financial Experience: Gay brings over 25 years of public company finance and accounting experience, having served as the company's SVP of Finance & Accounting since 2025, demonstrating his strong background and leadership in finance.
- Previous Roles Overview: Prior to joining Pelthos, Gay served as CFO of LNHC and held senior positions at Furiex Pharmaceuticals, further enhancing his expertise in the biopharmaceutical sector.
- Future Growth Outlook: Pelthos Therapeutics is actively driving continued momentum for ZELSUVMI and plans to expand product launches through 2027, reflecting the company's confidence in future market opportunities.
See More
Pelthos Therapeutics Appoints New CFO John M. Gay
- Executive Change: Pelthos Therapeutics has appointed John M. Gay as Chief Financial Officer effective April 10, 2026, succeeding Francis Knuettel II, who held the position since July 2025, indicating a strategic leadership transition during the company's growth phase.
- Financial Expertise: John M. Gay has served as Senior Vice President of Finance & Accounting at Pelthos for a year and brings over 25 years of public company finance and accounting experience, having held CFO roles at several publicly traded companies, showcasing Pelthos' confidence in his financial management capabilities.
- Strategic Implications: CEO Scott Plesha highlighted Gay's key role in establishing and launching Pelthos, indicating that the company is preparing for future commercial growth and market expansion, thereby strengthening its position in the biopharmaceutical industry.
- Acknowledgment of Predecessor: The company expressed gratitude for the contributions of former CFO Francis Knuettel II, particularly during the merger with Channel Therapeutics and two significant capital raises, reflecting Pelthos' emphasis on team stability and experience transfer.
See More
Pelthos Appoints New Chief Financial Officer
- Executive Transition: Pelthos Therapeutics has appointed John M. Gay as Chief Financial Officer effective April 10, 2026, succeeding Francis Knuettel II, who held the position since July 2025, indicating ongoing leadership optimization to support future growth.
- Financial Leadership Experience: John M. Gay has served as Senior Vice President of Finance & Accounting at Pelthos for a year and brings over 25 years of public company finance and accounting experience, enhancing the company's financial management expertise.
- Commitment to Business Growth: CEO Scott Plesha noted that Gay played a key role in establishing and launching Pelthos, and his appointment as CFO aims to continue driving the company's commercial momentum, reflecting confidence in future development.
- Capital Raising Context: During Knuettel's tenure, Pelthos successfully completed two significant capital raises, and Gay's appointment is viewed as a strategic continuation of the company's integration and capital operations post-merger, aimed at further solidifying its market position.
See More
Pelthos Initiates Clinical Trial for CT2000 Eye Pain Treatment
- Clinical Trial Launch: Pelthos Therapeutics announced the initiation of a Phase 1b/2a clinical trial for CT2000 in Australia, with the first patient successfully dosed, marking a significant advancement in the company's eye pain treatment pipeline.
- Drug Potential Assessment: CT2000, a NaV1.7 inhibitor, aims to treat acute and chronic ocular pain associated with dry eye disease, with animal study results suggesting broad applications in various pain indications, potentially offering new therapeutic options for patients.
- Market Outlook: The global chronic ocular pain market is projected to reach $5.3 billion by 2032, positioning Pelthos' CT2000 to capture a significant share of this rapidly growing market and address unmet patient needs.
- Innovative Trial Design: The clinical trial features an adaptive design with a maximum tolerated dose study over 28 days, with results expected by the end of 2026, where successful clinical data could lay the groundwork for future commercialization efforts.
See More
Pelthos Therapeutics Reports Strong Q4 2025 Earnings Growth
- Significant Revenue Growth: Pelthos Therapeutics reported a net product revenue increase from $7.1 million in Q3 2025 to $9.1 million in Q4 2025, marking a 28% growth that indicates strong market demand for ZELSUVMI and improved overall financial performance.
- Surge in Prescriptions: ZELSUVMI prescriptions surged by 129% from Q3, reaching 6,232 units, reflecting not only the product's growing acceptance in the market but also the company's successful shift towards direct patient dispensing, which is expected to further drive revenue growth.
- Product Portfolio Expansion: The acquisition of FDA-approved products Xepi and Xeglyze, set to launch in 2027, enhances Pelthos's product line, strengthens market competitiveness, and provides new revenue growth avenues for the future.
- Improved Financial Position: As of December 31, 2025, Pelthos's cash balance rose to $18 million from $14.2 million in Q3, demonstrating effective cost control and operational optimization, thereby laying a solid foundation for future business expansion.
See More
Pelthos Therapeutics Reports Q4 Losses Despite Revenue Beat
- Disappointing Earnings: Pelthos Therapeutics reported a Q4 GAAP EPS of -$6.87, missing expectations by $3.84, indicating significant challenges in profitability that could undermine investor confidence.
- Slight Revenue Growth: Despite the EPS miss, Pelthos achieved revenue of $9.39M, beating market expectations by $0.3M, suggesting that the company still has some growth potential in sales, which may support future business development.
- Financing Initiative: Pelthos Therapeutics announced a $50 million senior secured loan facility, which will provide necessary liquidity to help stabilize its operations and R&D efforts, despite its current financial challenges.
- Market Reaction Analysis: Following the earnings report, market reactions to Pelthos may be influenced by its profitability and financing plans, prompting investors to closely monitor future strategic adjustments and market performance.
See More
